Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength?

Stock Performance - Eton Pharmaceuticals shares surged 10.8% to close at $16.24 in the last trading session, supported by higher-than-average trading volume [1] - The stock has gained 15.8% over the past four weeks [1] Recent Developments - The company acquired Galzin (zinc acetate), an FDA-approved treatment for Wilson Disease, with plans to commercialize it in the US in Q1 2025 [2] - Eton also secured European rights to the product, marketed as Wilzin in Europe [2] Financial Expectations - Eton is expected to post a quarterly loss of$ 0.02 per share, representing a 77.8% year-over-year improvement [3] - Revenue is projected at $10.68 million, up 46.1% from the year-ago quarter [3] - The consensus EPS estimate has been revised 20% lower over the last 30 days [4] Industry Context - Eton operates in the Zacks Medical - Biomedical and Genetics industry [4] - Legend Biotech, another company in the same industry, saw its shares rise 0.7% to$ 37.69 in the last session [4] - Legend Biotech has returned 14.2% over the past month [4] - Legend Biotech's consensus EPS estimate for the upcoming report has changed -2.4% to -$0.32, representing a 20% improvement from the year-ago period [5]